company focusing on niche pharmaceutical products, are proud to announce a strategic collaboration aimed at advancing pharmaceutical innovation.
Under the terms of this collaboration agreement, ARTES Biotechnology and Basic Pharma will harness their respective expertise, cutting-edge technologies, and marketing strategies for the development and production of nonGMP recombinant proteins in a first step. This initial phase will pave the way for subsequent upgrades to meet Good Manufacturing Practice (GMP) pharmaceutical standards. The overarching objective of this alliance is to establish a streamlined supply chain process that expedites time-to-market for new pharmaceutical products.
The inaugural product to emerge from this collaboration is Human Serum Albumin (HSA), derived from the Hansenula polymorpha yeast. This initiative is partially funded by the BioMan4R2 project within the European SMP COSME program, focusing on EU resilience efforts in the health field on Biomanufacturing and MedTech areas (BMT).
ARTES Biotechnology’s Managing Director, Michael Piontek, remarked, “This alliance marks the first step in realizing our new strategy offering research reagents for non-human applications. Together with Basic Pharma, today we start with Human Serum Albumin produced from our proprietary yeast Hansenula. Tomorrow, we will expand this portfolio with sales of further enzymes, antigens and functional proteins.”
Ralph Bosmans, Manager of Biotechnology at Basic Pharma, expressed his enthusiasm for the collaboration: “We are delighted to join forces with ARTES Biotechnology on this venture. The synergy between ARTES Biotechnology’s proficiency in recombinant cell line development and our experience in pharmaceutical development is a perfect match.” Bob Kool, Managing director at Basic Pharma further emphasized: “We are excited to embark on this strategic journey alongside ARTES Biotechnology. The fusion of our pharmaceutical development experience with their cutting-edge protein production expertise promises a dynamic partnership.”
Under the terms of this collaboration agreement, ARTES Biotechnology and Basic Pharma will harness their respective expertise, cutting-edge technologies, and marketing strategies for the development and production of nonGMP recombinant proteins in a first step. This initial phase will pave the way for subsequent upgrades to meet Good Manufacturing Practice (GMP) pharmaceutical standards. The overarching objective of this alliance is to establish a streamlined supply chain process that expedites time-to-market for new pharmaceutical products.
The inaugural product to emerge from this collaboration is Human Serum Albumin (HSA), derived from the Hansenula polymorpha yeast. This initiative is partially funded by the BioMan4R2 project within the European SMP COSME program, focusing on EU resilience efforts in the health field on Biomanufacturing and MedTech areas (BMT).
ARTES Biotechnology’s Managing Director, Michael Piontek, remarked, “This alliance marks the first step in realizing our new strategy offering research reagents for non-human applications. Together with Basic Pharma, today we start with Human Serum Albumin produced from our proprietary yeast Hansenula. Tomorrow, we will expand this portfolio with sales of further enzymes, antigens and functional proteins.”
Ralph Bosmans, Manager of Biotechnology at Basic Pharma, expressed his enthusiasm for the collaboration: “We are delighted to join forces with ARTES Biotechnology on this venture. The synergy between ARTES Biotechnology’s proficiency in recombinant cell line development and our experience in pharmaceutical development is a perfect match.” Bob Kool, Managing director at Basic Pharma further emphasized: “We are excited to embark on this strategic journey alongside ARTES Biotechnology. The fusion of our pharmaceutical development experience with their cutting-edge protein production expertise promises a dynamic partnership.”
